J. McHutchison
About
J. McHutchison is a scholar working on Hepatology, Epidemiology and Rheumatology.
According to data from OpenAlex, J. McHutchison has authored 42 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hepatology, 17 papers in Epidemiology and 8 papers in Rheumatology. Recurrent topics in J. McHutchison's work include Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (11 papers) and Systemic Lupus Erythematosus Research (8 papers). J. McHutchison is often cited by papers focused on Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (11 papers) and Systemic Lupus Erythematosus Research (8 papers). J. McHutchison collaborates with scholars based in United States, Italy and Germany. J. McHutchison's co-authors include E. Läwitz, Nezam H. Afdhal, Andrew J. Muir, Stefan Zeuzem, R. Ghalib, Ira M. Jacobson, Mark Sulkowski, M. Shiffman, B. Van Baelen and Sebastian Meyer and has published in prestigious journals such as Hepatology, Journal of Hepatology and Journal of Viral Hepatitis.
In The Last Decade
J. McHutchison
40 papers receiving 329 citations
Peers
J. McHutchison
S Mauss Germany
E.J. Lawitz United States
Zayani Sims United States
Venkata Sasikiran Goteti United States
Takeaki Satoh Japan
Zunaira Awan Pakistan
A.C. Cardoso France
U. Alshüth Germany
Eiji Tanaka Japan
Christiane Stern France
Citations per year, relative to J. McHutchison J. McHutchison (= 1×)
peers
S Mauss
Countries citing papers authored by J. McHutchison
Since
Specialization
Citations
This map shows the geographic impact of J. McHutchison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. McHutchison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. McHutchison more than expected).
Fields of papers citing papers by J. McHutchison
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. McHutchison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. McHutchison. The network helps show where J. McHutchison may publish in the future.
Co-authorship network of co-authors of J. McHutchison
This figure shows the co-authorship network connecting the top 25 collaborators of J. McHutchison. A scholar is included among the top collaborators of J. McHutchison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. McHutchison. J. McHutchison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lawitz, Eric, Robert Herring, Ziad Younes, et al.. (2018). Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH. Journal of Hepatology. 68. S57–S57.
2.
Ratziu, Vlad, A. Sanyal, Holger Hinrichsen, et al.. (2017). Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis. Journal of Hepatology. 66(1). S594–S595.
3.
Harrison, S., Vlad Ratziu, Mitchell L. Shiffman, et al.. (2017). Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis. Journal of Hepatology. 66(1). S159–S160.
4.
Shea, Patrick R., Gideon M. Hirschfield, M. Shiffman, et al.. (2017). Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S4–S5.
5.
Levy, Carlos Emílio, Christopher L. Bowlus, B. Mccolgan, et al.. (2017). Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. Journal of Hepatology. 66(1). S73–S73.
6.
Gane, Edward, K. Peter Etzkorn, G. Morelli, et al.. (2016). Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study. Journal of Hepatology. 64(2). S147–S148.
7.
Kadayıfçı, Abdurrahman, George Papatheodoridis, MF Yuen, et al.. (2015). Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB). Hepatology International.
8.
Chan, Henry Lik‐Yuen, Marı́a Buti, Patrick Marcellin, et al.. (2013). 761 COMPARISON OF SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS. Journal of Hepatology. 58. S309–S310.
9.
Thompson, A., Lorenzo Rossaro, R. Ghalib, et al.. (2013). 64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS. Journal of Hepatology. 58. S29–S29.
10.
Yu, Min, Simin Xu, Bo Han, et al.. (2012). 825 DEVELOPMENT AND MOLECULAR CHARACTERIZATION OF A ROBUST GENOTYPE 4 HEPATITIS C VIRUS SUBGENOMIC REPLICON. Journal of Hepatology. 56. S322–S322.
11.
Thompson, Amber, M. Diago, Graham R. Foster, et al.. (2010). 53 RELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND INSULIN RESISTANCE IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C. Journal of Hepatology. 52. S25–S25.
12.
Afdhal, Nezam H., Edoardo G. Giannini, Angelo Andriulli, et al.. (2010). 1185 ELTROMBOPAG IN CHRONIC LIVER DISEASE PATIENTS WITH THROMBOCYTOPENIA UNDERGOING AN ELECTIVE INVASIVE PROCEDURE: RESULTS FROM ELEVATE, A RANDOMISED CLINICAL TRIAL. Journal of Hepatology. 52. S460–S460.
13.
Sulkowski, Mark, M. Shiffman, Jonathan McCone, et al.. (2009). 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY. Journal of Hepatology. 50. S51–S52.
14.
McHutchison, J., et al.. (2009). Sequence variation of NS3 and NS4A in hepatitis C virus (HCV) replicons following exposure to ITMN-191 concentrations likely to encompass those achieved in human liver following clinical dosing. Journal of Viral Hepatitis. 16(6).
15.
Zeuzem, Stefan, Mark Sulkowski, E. Läwitz, et al.. (2009). 1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS. Journal of Hepatology. 50. S377–S377.
16.
Läwitz, E., Curtis Cooper, M. Rodríguez‐Torres, et al.. (2009). 92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION. Journal of Hepatology. 50. S37–S37.
17.
Manns, M.P., Andrew J. Muir, Nathalie Adda, et al.. (2009). 1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY. Journal of Hepatology. 50. S379–S379.
18.
Sulkowski, Mark, E. Läwitz, M. Shiffman, et al.. (2008). 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY. Journal of Hepatology. 48. S370–S371.
19.
McHutchison, J., et al.. (1999). Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.. PubMed. 5(4). 211–6.
20.
Stewart, Charles A., et al.. (1989). Unusual Pattern of Lung Uptake of Technetium-99m Sulfur Colloid Seen on the Liver Scan of a Patient with Pulmonary Tuberculosis. Clinical Nuclear Medicine. 14(4). 271–274.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by S Mauss Breakdown of academic impact, for papers by E.J. Lawitz Breakdown of academic impact, for papers by Zayani Sims Breakdown of academic impact, for papers by Venkata Sasikiran Goteti Breakdown of academic impact, for papers by Takeaki Satoh Breakdown of academic impact, for papers by Zunaira Awan Breakdown of academic impact, for papers by A.C. Cardoso Breakdown of academic impact, for papers by U. Alshüth Breakdown of academic impact, for papers by Eiji Tanaka Breakdown of academic impact, for papers by Christiane Stern